
Avidity Biosciences, Inc. Common Stock
RNA
RNA: Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
moreShow RNA Financials
Recent trades of RNA by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by RNA's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Aug. 01, 2023
-
Patent Title: Compositions and methods of treating muscle dystrophy Jul. 25, 2023
-
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 21, 2023
-
Patent Title: Nucleic acid-polypeptide compositions and uses thereof Feb. 14, 2023
-
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 14, 2023
-
Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Jan. 17, 2023
-
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Jan. 17, 2023
-
Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Dec. 13, 2022
-
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Nov. 15, 2022
-
Patent Title: Compositions and methods of treating muscle dystrophy Sep. 20, 2022
-
Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping Aug. 02, 2022
-
Patent Title: Nucleic acid-polypeptide compositions and uses thereof Jun. 21, 2022
-
Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping Apr. 26, 2022
-
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 22, 2022
-
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 15, 2022
-
Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping Nov. 23, 2021
-
Patent Title: Nucleic acid-polypeptide compositions and uses thereof Sep. 07, 2021
-
Patent Title: Anti-transferrin receptor antibodies and uses thereof Jun. 08, 2021
-
Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping May. 04, 2021
-
Patent Title: Anti-transferrin receptor antibodies and uses thereof Feb. 09, 2021
-
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Jan. 05, 2021
-
Patent Title: Egfr nucleic acids and uses thereof Dec. 29, 2020
-
Patent Title: Kras nucleic acids and uses thereof Dec. 08, 2020
-
Patent Title: Beta-catenin nucleic acids and uses thereof Nov. 24, 2020
-
Patent Title: Nucleic acid-polypeptide compositions and uses thereof Oct. 13, 2020
-
Patent Title: Nucleic acid-polypeptide compositions and uses thereof Sep. 29, 2020
-
Patent Title: Nucleic acid-polypeptide compositions and uses thereof Feb. 04, 2020
-
Patent Title: Nucleic acid-polypeptide compositions and uses thereof Nov. 26, 2019
Federal grants, loans, and purchases
Followers on RNA's company Twitter account
Number of mentions of RNA in WallStreetBets Daily Discussion
Recent insights relating to RNA
Recent picks made for RNA stock on CNBC
ETFs with the largest estimated holdings in RNA
Flights by private jets registered to RNA